In November 2025, the drugmaker Novo Nordisk announced that two large and much anticipated studies failed to find any benefit for its GLP-1 medicine in patients with early stage Alzheimers disease
Obeticholic acid protects against diabetic cardiomyopathy by activation of FXR/Nrf2 signaling in db/db mice
GLP-1 advantage: Portion-controlled, high-protein, and reheats in seconds
Rosehip (200mg) Natural antioxidant for skin wellness
There is a real physiological argument, though one that should be taken with appropriate skepticism until human data accumulates, about receptor downregulation and what hitting three pathways at maximum dose may do to the bodys endogenous signaling architecture over years of continuous use
GLP-1 injections are typically administered once a week, making it a convenient and easy-to-follow treatment option.